Form 8-K - Current report:
SEC Accession No. 0000950170-24-136042
Filing Date
2024-12-13
Accepted
2024-12-13 07:03:07
Documents
11
Period of Report
2024-12-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K glue-20241211.htm   iXBRL 8-K 47835
  Complete submission text file 0000950170-24-136042.txt   172010

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT glue-20241211.xsd EX-101.SCH 30670
13 EXTRACTED XBRL INSTANCE DOCUMENT glue-20241211_htm.xml XML 4891
Mailing Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118
Business Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40522 | Film No.: 241546777
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)